Issue 65 March - April 2015

Intratumoural drug metabolism and the disposition of anticancer agents: implications for clinical treatment

Pharmacokinetics within tumour cells play an important role in the development of resistance. A better understanding of the mechanisms involved is important for devising treatment strategies to extend tumour response.

Read More ...
Issue 65 March - April 2015

Knocking at the door of the global agenda setters

The World Oncology Forum is challenging global policy makers to face the reality that current approaches to controlling cancer are not fit for purpose. An invitation to Davos shows they may be listening, but do they yet understand the need for change?

Read More ...
Issue 65 March - April 2015

More toxic, better targeted: are we one step close to that magic bullet?

Could the new generation of antibody–drug conjugates herald a move away from conventional untargeted chemotherapy? Much will depend on how far – and in whom – their added benefit can justify the high cost of these technologically sophisticated drugs.

Read More ...
Issue 65 March - April 2015

Generic cancer drugs that we can trust

Generics markets are gearing up for the expiry of patents on some of the first targeted cancer drugs. ItÂ’s good news for greater access, but patients want reassurance that switching to generics wonÂ’t put them at risk.

Read More ...
Issue 65 March - April 2015

Side effects of targeted treatments: clinicians' perceptions, patients' realities

The side effects of targeted drugs are poorly documented, and their impact on patients frequently seriously underestimated and undertreated. Efforts to address these issues could improve survival as well as quality of life.

Read More ...